Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) CEO Brent Willis join's Proactive's Natalie Stoberman to share a significant licensing agreement with Rain Cage Carbon to develop nanocarbon-based contrast drugs for medical imaging.
Willis says the partnership aims to develop new contrast agents for the radiology drug market while also making Voyageur the first carbon-neutral pharmaceutical company in the industry.
He explains that Rain Cage Carbon's innovative technology allows Voyageur to extract carbon dioxide and other emissions, generating high-grade carbon for various applications. By leveraging this technology, Willis says Voyageur plans to create safer and more effective drugs using carbon 60 molecules.